ANIP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ANI Pharmaceuticals Inc (ANIP) is not a strong buy at the moment for a beginner, long-term investor. While the company has shown strong revenue growth, its declining net income and EPS, combined with neutral technical indicators and lack of significant trading signals, suggest waiting for clearer positive momentum or post-earnings clarity before investing.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 42.816, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 79.324, with key support at 76.077 and resistance at 82.571.
Guggenheim raised the price target to $124, citing increased Cortrophin sales estimates and a positive 2026 outlook.
Revenue growth of 53.58% YoY in Q3
Focus on innovative therapeutics in rare disease markets, indicating potential long-term growth.
Net income dropped by -196.82% YoY, and EPS fell by -188.98% YoY in Q3
Technical indicators show no strong bullish signals.
Stock trend analysis predicts a potential short-term decline of -0.12% to -2.74% over the next month.
In Q3 2025, revenue increased significantly by 53.58% YoY to $227.8M, but net income dropped by -196.82% YoY to $23.79M, and EPS fell by -188.98% YoY to 1.13. Gross margin improved to 49.07%, up 4.72% YoY.
Guggenheim maintains a Buy rating and raised the price target from $115 to $124, driven by positive sales outlook for Cortrophin and preliminary Q4 results.
